A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.
Sponsor: Chugai Pharma USA
A PHASE2/PHASE3 clinical study on Atherosclerosis and Coronary Restenosis, this trial is completed. The trial is conducted by Chugai Pharma USA and has accumulated 6 data snapshots since 2026. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chugai Pharma USA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Asheville, United States, Austin, United States, Boston, United States, Burlingame, United States, Des Moines, United States, Elyria, United States, Houston, United States, Jacksonville, United States, Kalamazoo, United States, La Jolla, United States and 17 more location s